==========

Sequence Listing could not be accepted due to errors.
See attached Validation Report.
If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).
Reviewer: Anne Corrigan
Timestamp: [year=2010; month=7; day=19; hr=10; min=51; sec=33; ms=7;]

==========

****

Reviewer Comments:

<210> 54
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> polylysine sequence

<400> 54

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

As an explanation of "<213> Artificial Sequence", the above <223> response needs more inforamtion regarding the source of the genetic material: it is obvious that this is a polylysine sequence. Same in the <223> response in Sequence 62.

<160> 50

<210> 62
<211> 27
<212> DNA
<213> Artificial Sequence

Although the above <160> response is "50", there are 62 sequences in the submitted file.

****

Validated By CRFValidator v 1.0.3

Application No: 10559758 Version No: 2.0

Input Set:

Output Set:

Started: 2010-07-16 13:05:09.442
Finished: 2010-07-16 13:05:13.391
Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 949 ms
Total Warnings: 62
Total Errors: 2
No. of SeqIDs Defined: 50
Actual SeqID Count: 62

Error code		Error Description
E	287	Invalid WIPO ST.2 date format; Use (YYYY-MM-DD) in <141>
W	213	Artificial or Unknown found in <213> in SEQ ID (1)
W	213	Artificial or Unknown found in <213> in SEQ ID (2)
W	213	Artificial or Unknown found in <213> in SEQ ID (3)
W	213	Artificial or Unknown found in <213> in SEQ ID (4)
W	213	Artificial or Unknown found in <213> in SEQ ID (5)
W	213	Artificial or Unknown found in <213> in SEQ ID (6)
W	213	Artificial or Unknown found in <213> in SEQ ID (7)
W	213	Artificial or Unknown found in <213> in SEQ ID (8)
W	213	Artificial or Unknown found in <213> in SEQ ID (9)
W	213	Artificial or Unknown found in <213> in SEQ ID (10)
W	213	Artificial or Unknown found in <213> in SEQ ID (11)
W	213	Artificial or Unknown found in <213> in SEQ ID (12)
W	213	Artificial or Unknown found in <213> in SEQ ID (13)
W	213	Artificial or Unknown found in <213> in SEQ ID (14)
W	213	Artificial or Unknown found in <213> in SEQ ID (15)
W	213	Artificial or Unknown found in <213> in SEQ ID (16)
W	213	Artificial or Unknown found in <213> in SEQ ID (17)
W	213	Artificial or Unknown found in <213> in SEQ ID (18)
W	213	Artificial or Unknown found in <213> in SEQ ID (19)

Input Set:

Output Set:

Started: 2010-07-16 13:05:09.442
Finished: 2010-07-16 13:05:13.391
Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 949 ms
Total Warnings: 62
Total Errors: 2
No. of SeqIDs Defined: 50
Actual SeqID Count: 62

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (20) This error has occured more than 20 times, will not be displayed
E 252	Calc# of Seq. differs from actual; 50 seqIds defined; count=62

SEQUENCE LISTING

<110> Hart, Stephen Lewis
Writer, Michele

<120> PEPTIDE LIGANDS

<130> ABL-012.1P US

<140> 10559758
<141> 2010-07-16

<150> PCT/EP2004/002421
<151> 2004-06-07

<150> GB 03 13132.3
<151> 2003-06-06

<160> 50

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = a
ny amino acid residue, Xaa at position 4 = any amino acid residue

<400> 1

Pro Xaa Xaa Xaa Thr
1 5

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells
<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa at position 3 = any amino acid residue

<400> 2

Pro Ser Xaa Ser
1

<210> 3

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid, Xaa at position 3 = any amino

acid having an amide side chain, Xaa at position 4 = any amino a
cid

<400> 3

Gln Xaa Xaa Xaa Gln
1 5

<210> 4

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue having an aliphatic si
de chain

<400> 4

Ser Xaa Ser
1

<210> 5

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 5

Pro Xaa Leu Xaa Thr
1 5

<210> 6

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 6

Pro Ala Leu Lys Thr
1 5

<210> 7

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 7

Pro Xaa Asn Xaa Thr
1   5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 8

Pro Ser Asn Ser Thr
1   5

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 9

Pro Pro Asn Thr Thr
1   5

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = an
y amino acid residue, Xaa at position 4 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = any amino acid resdue

<400> 10

Pro Xaa Xaa Xaa Thr Xaa
1   5

<210> 11

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = any amino acid residue

<400> 11

Pro Xaa Leu Xaa Thr Xaa
1 5

<210> 12

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = any amino acid residue

<400> 12

Pro Xaa Asn Xaa Thr Xaa
1 5

<210> 13

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (3)..(5)

<223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = a
ny amino acid residue, Xaa at position 5 = any amino acid residue

<400> 13

Xaa Pro Xaa Xaa Xaa Thr
1 5

<210> 14

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (3)..(5)

<223> Xaa at position 3 = any amino acid residue, Xaa at position 4 = a
ny amino acid residue, Xaa at position 5 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa at position 7 = any amino acid residue

<400> 14

Xaa Pro Xaa Xaa Xaa Thr Xaa
1 5

<210> 15

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 15

Ala Pro Ser Asn Ser Thr Ala
1 5

<210> 16

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 16

Ser Pro Ala Leu Lys Thr Val
1 5

<210> 17

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 17

Ser Thr Pro Pro Asn Thr Thr
1 5

<210> 18

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 18

Pro Ser Asn Ser
1

<210> 19

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 19

Pro Ser Leu Ser
1

<210> 20

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = Ala or Lys

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 20

Xaa Pro Ser Xaa Ser
1 5

<210> 21

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 21

Ala Pro Ser Asn Ser
1 5

<210> 22

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 22

Leu Pro Ser Leu Ser
1 5

<210> 23

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 23

Met Leu Pro Ser Leu Ser
1 5

<210> 24

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 24

Pro Met Leu Pro Ser Leu Ser
1 5

<210> 25

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 25

Ser Gln Lys Asn Pro Gln Met
1 5

<210> 26

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 26

Phe Gln Ser Gln Tyr Gln Lys
1 5

<210> 27

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 27

Met Ala Ser Ile Ser Met Lys
1 5

<210> 28

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 28

Asp Trp Trp His Thr Ser Ala
1 5

<210> 29

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 29

Ser His Val Lys Leu Asn Ser
1 5

<210> 30

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 30

Gln Leu Leu Thr Gly Ala Ser
1 5

<210> 31

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 31

Thr Ala Arg Asp Tyr Arg Leu
1 5

<210> 32

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 32

Phe Pro Arg Ala Pro His His
1 5

<210> 33

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 33

Ser Glu Trp Leu Ser Ala Leu
1 5

<210> 34

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 34

Ile Gly Gly Ile Arg Arg His
1 5

<210> 35

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 35

Tyr Thr Met Glu Phe Asn Arg
1 5

<210> 36

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<400> 36

Pro Ala Ala Tyr Lys Ala His
1 5

<210> 37

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = a
ny amino acid residue, Xaa at position 4 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa at position 6 = Ala or Val

<400> 37

Pro Xaa Xaa Xaa Thr Xaa
1 5

<210> 38

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue,

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue,

<400> 38

Pro Xaa Asn Xaa Thr
1 5

<210> 39

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A
sn or Leu, Xaa at position 4 = any amino acid residue

<400> 39

Pro Xaa Xaa Xaa Thr
1 5

<210> 40

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = any amino acid residue

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position = Thr or Ser

<400> 40

Pro Xaa Asn Xaa Thr
1 5

<210> 41

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa at position 1 = Ala or Leu

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa at position 4 = any amino acid residue

<400> 41

Xaa Pro Ser Xaa Ser
1 5

<210> 42

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(4)

<223> Xaa at position 2 = any amino acid residue, Xaa at position 3 = A
sn or Gln, Xaa at position 3 = any amino acid residue

<400> 42

Gln Xaa Xaa Xaa Gln
1 5

<210> 43

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide binding to dendritic cells

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa at position 2 = Leu or Ile

<400> 43

Ser Xaa Ser
1

<210> 44

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 44

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Ser His Val Lys Leu Asn Ser Cys Gly
20 25

<210> 45

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 45

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Ala Pro Ser Asn Ser Thr Ala Cys Gly
20 25

<210> 46

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 46

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gly

20 25

<210> 47

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 47

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Phe Pro Arg Ala Pro His His Cys Gly
20 25

<210> 48

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 48

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Asp Trp Trp His Thr Ser Ala Cys Gly
20 25

<210> 49

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 49

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Arg Arg Glu Thr Ala Trp Ala Cys Gly
20 25

<210> 50

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide derivative of the invention

<400> 50

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Ala Thr Arg Trp Ala Arg Glu Cys Gly
20 25

<210> 51
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 51

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Arg Arg Glu Glu Trp Ala Cys Gly

20 25

<210> 52
<211> 28
<212> PRT
<213> Artificial Sequence

<220>
<223> Peptide derivative of the invention

<400> 52

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

Gly Ala Cys Met Ala Ser Ile Ser Met Lys Cys Gln
20 25

<210> 53
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> integrin-binding peptide

<400> 53

Arg Arg Glu Thr Glu Trp Ala
1 5

<210> 54
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> polylysine sequence

<400> 54

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

<210> 55
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> hydrophobic spacer sequence

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> x = epsilon-amino hexanoic acid residue

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> x = epsilon-amino hexanoic acid residue